跳至主要内容
临床试验/NCT06042699
NCT06042699招募中不适用

Kids With Iron Deficiency and Scoliosis (KIDS) Study

Columbia University2 个研究点 分布在 1 个国家目标入组 275 人开始时间: 2024年1月11日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
275
试验地点
2
主要终点
Incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion

研究概览

简要总结

This study is a randomized controlled trial of preoperative oral iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in adolescents undergoing scoliosis surgery.

Research Question(s)/Hypothesis(es):

Primary

  • Iron supplementation will reduce the incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion.

Secondary

  • Iron supplementation will reduce postoperative neurocognitive functional declines in iron deficient scoliosis patients undergoing spinal fusion.
  • Iron supplementation will improve patient-reported physical functioning in iron deficient scoliosis patients undergoing spinal fusion.

详细描述

Adolescents undergoing spinal fusion surgery for scoliosis are poised to benefit from preoperative iron supplementation. Spinal fusion carries a risk of large surgical blood losses and perioperative red blood cell transfusion, which are associated with adverse outcomes in this population. These patients are mostly adolescent females, a group more susceptible to iron deficiency and resulting anemia at baseline due to iron losses with menses, and who suffer an additional insult to iron stores during surgery. Nevertheless, iron status is not routinely monitored in this setting and there is no standard of care for preoperative iron supplementation. Iron is a nutritionally essential trace element important not only for red blood cell production, but also for muscle function and neurotransmitter synthesis and signaling. Therefore, the treatment of preoperative iron deficiency is an important target for optimizing hemoglobin prior to surgery, reducing transfusion rates and associated complications such as alloimmunization, and improving patient outcomes. On its own and as the primary cause of anemia, iron deficiency was identified by the investigator's team as the only risk factor for transfusion which is modifiable preoperatively.

In addition, iron supplementation is shown to alleviate impairments of physical and cognitive capacity associated with even mild forms of iron deficiency in adolescent females. A pilot study conducted at the investigator's institution identified iron deficiency in 36% of scoliosis patients prior to surgery, with preoperative iron status highly correlated with iron status during surgical recovery. Consequently, the investigator plans to examine iron deficiency as a modifiable risk factor for transfusion and impaired postoperative cognitive and physical capacity in this vulnerable population. Previous trials of brief iron interventions in high-risk adult surgical patients, mostly with unknown iron status, do not inform the care of iron deficient adolescents and were not designed to address postoperative functional outcomes. This study will therefore perform a single-center randomized controlled trial in which adolescents with scoliosis will be screened for iron deficiency (n = ~275), and iron-deficient adolescents with scoliosis (n = ~90) will be randomized to a preoperative regimen of daily oral iron or placebo, to test the hypotheses that preoperative iron supplementation 1) reduces the rate of red blood cell transfusion, 2) improves postoperative neurocognition compared to a preoperative baseline, and 3) improves patient-reported physical functioning during recovery. Results will ultimately improve outcomes in this vulnerable pediatric population and provide evidence for patient blood management approaches to reduce transfusions amid recent severe blood shortages.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Placebo tablets will be indistinguishable from iron tablets. Group allocation will not be accessible to participants, care providers, investigators, or outcomes assessors.

入排标准

年龄范围
10 Years 至 26 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 10-26 years old;
  • diagnosis of scoliosis or kyphosis;
  • self-reported ability to swallow a tablet;
  • spinal fusion procedure planned approximately 6 to 24 weeks from an orthopedic surgical clinic visit at which patient agrees to phlebotomy for screening blood work;
  • serum ferritin less than or equal to 25 µg/L.

排除标准

  • taking or planning to take iron-containing supplement on patient's own volition, and not willing to stop for duration of study;
  • taking or planning to take iron-containing supplement as prescribed or recommended under the care of a physician;
  • Hg <10mg/dL if post-menarchal, Hg < 11 if premenarchal or male
  • C-reactive protein > 10 mg/L
  • receiving nutritional support by report in the medical chart;
  • self-reported history of hypersensitivity reaction to iron-containing supplements;
  • self-reported history of or suspected non-iron deficient hematologic disorder;
  • self-reported history of iron overloaded state such as hereditary hemochromatosis or hemosiderosis;
  • objection to receiving red blood cell transfusions;
  • current pregnancy (by self-report);
  • patient or parent decides against study participation.

研究组 & 干预措施

Observational follow-up

No Intervention

Participants who do not qualify for randomization may be invited to complete study measures through postoperative follow-up as part of an observational study.

Oral ferrous sulfate

Experimental

Participants will receive oral ferrous sulfate tablets, 325mg (65mg elemental iron). Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.

干预措施: Oral ferrous sulfate (Dietary Supplement)

Oral placebo tablets

Placebo Comparator

Participants will receive placebo tablets. Tablets are to be taken once daily for 3-6 months prior to surgery as time allows.

干预措施: Oral placebo tablet (Dietary Supplement)

结局指标

主要结局

Incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion

时间窗: 4 to 30 days

The patients that received a red blood cell transfusion either during procedure or postoperatively during t surgical hospitalization will be tallied.

次要结局

  • Percentage of Patients that experienced postoperative decline in neurocognitive function(3-6 months)
  • Percentage of patients that experienced postoperative decline in self-reported physical capacity(3-6 months)
  • Volume of perioperative RBC transfusion(4 to 30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lisa Eisler

Assistant Professor of Anesthesiology

Columbia University

研究点 (2)

Loading locations...

相似试验